Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphttheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) – Pipeline Review, H2 2017’, provides in depth analysis on Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)

The report reviews Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

AstraZeneca Plc

BeiGene Ltd

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Ildong Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tesaro Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Overview 8

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 16

Products under Development by Universities/Institutes 25

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Therapeutics Assessment 27

Assessment by Mechanism of Action 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Companies Involved in Therapeutics Development 32

AbbVie Inc 32

AstraZeneca Plc 33

BeiGene Ltd 35

Checkpoint Therapeutics Inc 36

Clovis Oncology Inc 36

Ildong Pharmaceutical Co Ltd 37

Jiangsu Hengrui Medicine Co Ltd 37

Shanghai Acebright Pharmaceuticals Group Co Ltd 38

Tesaro Inc 38

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Drug Profiles 40

2X-121 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ABT-767 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AZ-0108 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

AZD-1775 + olaparib - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AZD-6738 + olaparib - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

BGB-290 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BGBA-317 + BGB-290 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

cediranib maleate + olaparib - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CK-102 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

IDX-1197 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

niraparib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

olaparib - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

rucaparib camsylate - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

SC-10914 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

SHR-3162 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

SOMCL-9112 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

veliparib ER - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

YHP-743 - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Dormant Products 103

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Discontinued Products 104

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Product Development Milestones 105

Featured News & Press Releases 105

Oct 24, 2017: Myriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer 105

Oct 23, 2017: Astrazeneca And MSD Rapidly Advance Lynparza In Japan With A Second Regulatory Submission 105

Oct 18, 2017: Myriad’s BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza (olaparib) in Metastatic Breast Cancer 105

Oct 18, 2017: US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review 106

Oct 09, 2017: Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer 106

Sep 29, 2017: Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer 107

Sep 21, 2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement 107

Sep 15, 2017: TESARO Receives Positive CHMP Opinion for ZEJULA 108

Sep 13, 2017: Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet 109

Sep 11, 2017: TESARO Summarizes ZEJULA Data Presented at 2017 ESMO Annual Meeting 110

Sep 08, 2017: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress 113

Sep 07, 2017: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 114

Aug 30, 2017: Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress 117

Aug 30, 2017: BeiGene Announces Presentations on its PARP inhibitor BGB-290 at the European Society for Medical Oncology 2017 Congress 118

Aug 25, 2017: TESARO Announces Eight Poster Presentations on ZEJULA at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 118

Appendix 121

Methodology 121

Coverage 121

Secondary Research 121

Primary Research 121

Expert Panel Validation 121

Contact Us 121

Disclaimer 122

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 24

Number of Products under Investigation by Universities/Institutes, H2 2017 25

Products under Investigation by Universities/Institutes, H2 2017 26

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Stage and Route of Administration, H2 2017 29

Number of Products by Stage and Molecule Type, H2 2017 31

Pipeline by AbbVie Inc, H2 2017 32

Pipeline by AstraZeneca Plc, H2 2017 34

Pipeline by BeiGene Ltd, H2 2017 35

Pipeline by Checkpoint Therapeutics Inc, H2 2017 36

Pipeline by Clovis Oncology Inc, H2 2017 37

Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 37

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 38

Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H2 2017 38

Pipeline by Tesaro Inc, H2 2017 39

Dormant Projects, H2 2017 103

Discontinued Products, H2 2017 104

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Routes of Administration, H2 2017 28

Number of Products by Stage and Routes of Administration, H2 2017 28

Number of Products by Molecule Types, H2 2017 30

Number of Products by Stage and Molecule Types, H2 2017 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports